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Hyperekplexia is a rare, but potentially fatal, neuromotor disorder characterized by exaggerated startle reflexes and hypertonia in
response to sudden, unexpected auditory or tactile stimuli. This disorder is primarily caused by inherited mutations in the genes
encoding the glycine receptor (GlyR) 1 subunit (GLRA1) and the presynaptic glycine transporter GlyT2 (SLC6A5). In this study,
systematicDNAsequencingofGLRA1 in 88newunrelatedhumanhyperekplexia patients revealed 19 sequence variants in 30 index cases,
of which 21 cases were inherited in recessive or compound heterozygote modes. This indicates that recessive hyperekplexia is far more
prevalent than previous estimates. From the 19 GLRA1 sequence variants, we have investigated the functional effects of 11 novel and 2
recurrentmutations. The expression levels and functional properties of these hyperekplexiamutantswere analyzed using a high-content
imaging system and patch-clamp electrophysiology. When expressed in HEK293 cells, either as homomeric 1 or heteromeric 1
GlyRs, subcellular localization defectswere themajormechanismunderlying recessivemutations.However,mutantswithout trafficking
defects typically showed alterations in the glycine sensitivity suggestive of disrupted receptor function. This study also reports the first
hyperekplexia mutation associated with a GlyR leak conductance, suggesting tonic channel opening as a new mechanism in neuronal
ligand-gated ion channels.
Introduction
Glycine receptors (GlyRs) are members of the pentameric Cys-
loop ion channel superfamily and major determinants of inhibi-
tory neurotransmission in the retina, spinal cord, and brainstem
(Lynch, 2004). Each GlyR subunit comprises a large N-terminal
ligand-binding domain (LBD) and membrane-spanning region
comprising four -helical domains (M1–M4). At least four GlyR
subunits exist in the humanbrain (1,2,3, and), assembling
predominantly as 123 heteropentamers (Lynch, 2004; Grudz-
inska et al., 2005). Mutations in the GlyR 1 (GLRA1) and GlyR
 (GLRB) subunit genes are associated with startle disease/hy-
perekplexia with 29 distinct GLRA1 mutations in 56 index cases
and families described (OMIM: 149400) (Shiang et al., 1993; Rees
et al., 2002; Harvey et al., 2008). Recently, defects in a presynaptic
glycine transporter gene (SLC6A5) have been identified in hu-
man hyperekplexia (Rees et al., 2006).
Hyperekplexia is a rare, but potentially fatal, neurological dis-
order characterized by an abnormal startle reflex and an exagger-
ated muscle stiffness in response to sudden, unexpected auditory
or tactile stimuli (Harvey et al., 2008). The symptoms are most
severe in neonates and infants in whom intense hypertonicity can
lead to apnea episodes and prolonged cyanotic attacks. The hy-
pertonia, which is predominantly in the trunk and lower limbs,
often diminishes during the first year of life, but the pathological
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startle response, which can provoke unprotected falls and result
in injury, can remain throughout development and into adult-
hood (Andermann et al., 1980).
Previously identified dominant GLRA1 mutations are typi-
cally missense mutations predominantly located either in or near
the M2 pore-lining domain of the GlyR 1 subunit (Saul et al.,
1999; Harvey et al., 2008). The functional consequences of dom-
inant GLRA1mutations demonstrate that mutations in these re-
gions exert dominant-negative effects by altering the allosteric
signal transduction process coupling agonist binding to ion-
channel gating (Harvey et al., 2008). By contrast, all nonsense and
frameshift mutations in GLRA1 are associated with recessive
cases of hyperekplexia with asymptomatic carrier parents, prov-
ing that hyperekplexia is not susceptible to haploinsufficiency
(Brune et al., 1996; Rees et al., 2001). Functional studies of reces-
sive missense mutations revealed a reduction in whole-cell cur-
rents, possibly because of the defects in GlyR trafficking or a
decrease of membrane expression (Lynch et al., 1997; Rees et al.,
2001; Humeny et al., 2002; Villmann et al., 2009).
Here, we present the systematic sequencing of GLRA1 in 88
unrelated hyperekplexia probands in an international screening
program that identified 5 dominant and 14 recessiveGLRA1mu-
tations within 30 index case families of which 12 are novel. A
proportion of these novel mutations, including 10 recessive mu-
tations, were characterized in a recombinant heteromeric GlyR
1 expression system. This study reveals that the pathophysio-
logical mechanisms of dominant mutations differ from those of
recessive mutations and that, contrary to established dogma, re-
cessive hyperekplexia is decidedly more common than dominant
hyperekplexia on a population basis. Last, we present a novel
pathophysiological mechanism for hyperekplexia and neuronal
ligand-gated channels: a dominant1 subunitmutation (Y128C)
that produces an open confirmation and tonic conductance
through heteromeric 1 GlyRs.
Materials andMethods
Patients and cases.With informed consent procedures in place, patients
with a clinical diagnosis of hyperekplexia were ascertained by referral
from neurologists, pediatricians, or clinical geneticists from interna-
tional centers. Eighty-eight unrelated index patientswere included in this
population study after phenotypic evaluation. Clinical inclusion criteria
included a nonhabituating startle response (positive nose tap test), his-
tory of infantile hypertonicity, and an exclusion of phenocopies such as
startle epilepsy (Harvey et al., 2008). The gender of patients is indicated
in Table 1.
Molecular genetics. The exons and exon–intron boundaries of GLRA1
were amplified using primers designed using the Primer 3.0 program
(MIT). To avoid allelic dropout, all primers were placed in intronic re-
gions that were devoid of single-nucleotide polymorphisms (SNPs) as
revealed by National Center for Biotechnology Information (NCBI) da-
tabases (Tester et al., 2006). Following conventional PCR protocols with
patientDNA, PCRproductswere purifiedwithQIAquick purification kit
(QIAGEN) and directly sequenced using BigDye terminators and an
ABI3100 automated Sequencer (Applied Biosystems). Frequency of
SNPs or mutations was assessed in 100 control alleles using restriction
fragment length polymorphism if a suitable restriction enzymewas avail-
able, or matrix-assisted laser desorption ionization time-of-flight mass
spectrometry using protocolsmodified from those of Powell et al. (2004).
In addition to sequence screening, all DNA samples were screened for
large deletions or insertions in GLRA1 using a MLPA (Multiplex
Ligation-Dependent Probe Amplification) DNA detection kit following
the manufacturer’s protocol (MRF). For samples with the recurrent
Exon1-7 deletion mutation, the previously identified breakpoints were
confirmed by using a PCR assay as previously described (Becker et al.,
2006).
Mutagenesis and expression of constructs. Full-length human GlyR 1
and  subunits were cloned into the vector pRK5 (Rees et al., 2006) and
the pIRES2-EGFP plasmid vector (Clontech), respectively. Mutations
were introduced into pRK5-hGlyR1 using the QuikChange Site-
Directed Mutagenesis kit (Stratagene). All expression constructs were
confirmed by sequencing the entire coding region. Wild-type (WT) or
mutant GlyR 1 subunits were transiently expressed in human embryonic
Table 1. Details of hyperekplexia mutations identified in this study
Case Sequence
Classification of
mutation Mutants Protein position Gender Mode of inheritance References
1–6 Exons 1-7 (Homo) Deletion del Ex1-7 NA 3F, 3M R Brune et al., 1996;
Gilbert et al., 2004
7 G574T Missense R65L  Mat N-terminal M R NovelExons 4-7 Deletion del Ex4-7 Pat NA Novel
8 C573T (Homo) Missense R65W N-terminal M R Novel
9 931-932CT (Homo) Deletion L184fs21X N-terminal M R Novel
10 931-932CT Deletion L184fs21X  Pat N-terminal M R NovelG687A Missense E103K Mat N-terminal R Novel
11 A764G Missense Y128C N-terminal M D Novel
12 A874G Missense D165G N-terminal F R Novel
13 C971A Nonsense Y197X  Pat N-terminal M R NovelC986A Nonsense Y202X Mat N-terminal Rees et al., 2001
14 C971A (Homo) Nonsense Y197X N-terminal F R Novel
15–17 C986A (Homo) Nonsense Y202X N-terminal 1F, 2M R Rees et al., 2001
18 G1074A Missense S231N  * M1 M R NovelC1257A Nonsense S296X M3 R Bellini et al., 2007
19 C1128A Missense P250T M1–M2 M D Saul et al., 1999
20 C1134T (Homo) Missense R252C M1–M2 M R Novel
21, 22 G1141A (Homo) Missense G254D M2 2M R Novel
23 C1174T Missense T265I M2 M D Novel
24–27 G1192A Missense R271Q M2–M3 2F, 2M D Shiang et al., 1993
28, 29 G1404A Missense G342S M3–M4 1F, 1M D Rees et al., 2001
30 G1555A (Homo) Missense R392H M3–M4 M R Vergouwe et al., 1999
Mat, Maternal; Pat, paternal; F, female; M, male; R, recessive; D, dominant. *Parental DNA not available; however, case 18’s unaffected male sibling has only one of the heterozygous mutations, namely, S296X, indicating by default that
S231N and S296X are present on different alleles.
Chung et al. •Mechanisms of Hyperekplexia Mutations J. Neurosci., July 14, 2010 • 30(28):9612–9620 • 9613
kidney (HEK293) cells using Effectene transfection reagent (QIAGEN) or a
calcium phosphate technique. For experiments involving homomeric
GlyRs, pRK5-hGlyR1 was cotransfected with the pEGFPC1 vector
(Clontech) as a transfectionmarker in a 1:1 ratio. For heteromeric GlyRs,
1 and  subunit expression constructs were transfected at a DNA ratio
of 1:10. Homomeric 1 subunit or heteromeric 1 subunit GlyRs were
distinguished by applying 100 M picrotoxin (PTX), which inhibits ho-
momeric GlyRs but not heteromeric GlyRs (Lynch, 2004). Twenty-four
hours after transfection, cells were washed twice, and recordings were
made at room temperature (RT) within the following 24–48 h.
Electrophysiology patch clamping. Whole-cell patch-clamp recordings
were performed on HEK293 cells placed in an external solution consist-
ing of the following (in mM): 140 NaCl, 5 KCl, 2 CaCl2, 1 MgCl2, 10
HEPES, 10 glucose, adjusted to pH 7.4 with NaOH. Electrodes were
pulled from borosilicate glass hematocrit tubing (Vitrex) with a horizon-
tal puller (P97; Sutter Instrument) and heat polished. The electrodes
have resistances of 1-3 M when filled with an internal pipette solution
consisting of the following (in mM): 145 CsCl, 2 CaCl2, 2 MgCl2, 10
HEPES, 10 EGTA, adjusted to pH 7.4 with NaOH. Glycine-gated cur-
rents were recorded using the whole-cell patch-clamp configuration at a
holding potential of 40 mV. Solutions were applied to whole cells via
gravity through parallel microtubules. The perfusion system was under
the control of a manual micromanipulator and solution exchange was
routinely complete within 100ms between adjacent tubes. Currents were
digitized at 1 kHz, filtered at 500 Hz, and digitally recorded on a com-
puter using anAxopatch 1D amplifier and pClamp9 software (Molecular
Devices). The half-maximal concentration (EC50) and Hill coefficient
(nH) values were calculated for individual glycine concentration–re-
sponse relationships using the Hill equation fitted by a nonlinear least-
squares analysis (SigmaPlot 9.0). For quantifying tonic channel activity,
voltage rampswere applied from80 to80mVover a 2 s interval, from
a holding potential of40 mV.
High-content screening system. Cells were imaged using an automated
high-content screening system using YFP-I152L fluorescence as an indi-
cator of Cl influx rate (Kruger et al., 2005; Gilbert et al., 2009). Briefly,
HEK293 cells were cotransfected with mutant or WT pRK5-hGlyR1
and pcDNA3.1-YFP-I152L and plated into a 384-well plate (2.5 103
cells/well).Within the following 24–32 h, cells were incubated in 25l of
standard NaCl control solution (140mMNaCl, 5 mMKCl, 2mMCaCl2, 1
mMMgCl2, 10 mMHEPES, and 10 mM glucose, pH 7.4 using NaOH) for
1 h, and 10 different glycine concentrations were prepared in NaI solu-
tion (140 mM NaI, 5 mM KCl, 2 mM CaCl2, 1 mM MgCl2, 10 mM HEPES,
and 10 mM glucose, pH 7.4 using NaOH). Fluorescence images of each
well were obtained twice, before and after the application of NaI solution
containing a varying concentration of glycine. The percentage fluores-
cent change (quench) was calculated using the following equation: (1
(Ffinal/Finit)*100), where Finit is the initial (or control) fluorescence value
before the application of glycine, and Ffinal is the fluorescence level after
the application of glycine. Concentration–response curves were con-
structed by pooling results from two wells exposed to the same glycine
concentration. Averaged fluorescence values were used to construct a
dose–response curve, which was fitted as described above (SigmaPlot
9.0). For each mutant, screening was replicated at least three times.
Biotinylation. Two days after transfection, surface expression of GlyR
1 subunits in HEK293 cells were investigated using a cell membrane-
impermeable reagent Sulfo-NHS-LC-Biotin (Pierce Biotechnology)
based on the manufacturer’s protocol. Briefly, transfected HEK293 cells
in a 100 ml dish were washed twice with ice-cold PBS buffer and incu-
bated in 10ml of PBS containing 0.25mg/ml Sulfo-NHS-SS-biotin for 30
min at 4°C with gentle shaking. Excess biotinylating reagent was then
removed by adding quenching solution (Pierce) followed by washing the
cells twice with TBS (Pierce). Cells were lysed using a lysis buffer (Pierce)
supplemented with protease inhibitors (Pierce). To remove the non-
soluble fraction, the lysate was centrifuged at 14,000  g for 15 min at
4°C, and then the clear supernatant was removed for additional analysis.
The total protein concentration was measured with a DC Protein Assay
(Bio-Rad), and 50 g of total protein was removed for immunoblotting
analysis. To separate biotin-labeled surface proteins, 500 g of protein
was incubated with 125 l of immobilized biotin-binding protein, Neu-
trAvidin gels (Pierce) for 1 h at RT. The biotin protein attached beads
were then washed four times with a wash buffer (Pierce). The surface
proteins were isolated from NeutrAvidin linked biotin molecule by in-
cubating with 100 l of a sample buffer containing 50 mM reducing
reagent (DTT) for 1 h at RT. The surface proteins were then eluted by
centrifugation at 1000  g for 2 min. Total protein lysates were also
obtained from cells transfected with mutant or WT GlyR 1 and  sub-
units by lysing cells as described above, but without the biotinylation
labeling. Proteins in the whole-cell lysates or cell surface proteins were
analyzed by Western blotting with an antibody against the GlyR 1 sub-
unit (1:1500; Millipore). An anti--actin antibody (1:7000; Abcam) was
used as a control to confirm that intracellular proteins were not labeled
with biotin. The intensity of the immunoreactivity signal was quantified
with ImageJ software (http://rsb.info.nih.gov/ij).
Statistical analysis. Data were analyzed using SigmaPlot (version 9.0;
Systat Software) or GraphPad Prism (version 3.02; GraphPad Software)
and expressed asmean SEM. Statistical significancewas determined by
Student’s t test and considered to be significant at p 0.05.
Molecular modeling. Structural modeling of GlyR 1 WT and mutant
proteins was performed using a homology modeling pipeline built with
the Biskit structural bioinformatics platform (Gru¨nberg et al., 2007),
which scans the entire Protein Data Bank (PDB) database for candidate
homologies. The best match attained for GlyR 1 was based on 26%
identity with the crystal structure of the Torpedo 12 nicotinic ACh
receptor (nAChR) (Unwin, 2005) (PDB: 2BG9). Our pipeline workflow
incorporates the NCBI tools platform (Wheeler et al., 2007), including
the BLAST program (Altschul et al., 1990) for similarity searching of
sequence databases. T-COFFEE (Notredame et al., 2000) was used for
alignment of the test sequencewith the template.Homologymodels were
generated over 10 iterations of the MODELLER program (Eswar et al.,
2003). The Torpedo nAChR pentamer was subsequently used as the tem-
plate for the assembly of the pentameric GlyR (2,3), built by overlay-
ing 1 (WT or mutant) and  subunits on the subunit positions of the
Torpedo nAChR pentamer using Chimera (Pettersen et al., 2004).
Results
Mutation analysis ofGLRA1 in hyperekplexia
A total of 88 index cases with confirmed hyperekplexia were
screened for genetic variation in the entire coding and splice site
regions of GLRA1. All sequence variations were regarded as mu-
tations after exclusion from a panel of human controls. Direct
sequencing analysis revealed 19 mutations within 30 hyperek-
plexia index cases, of which 12mutations were novel and 7 of the
mutations were discovered inmore than one index case (Table 1;
supplemental Fig. S1A–D, available at www.jneurosci.org as sup-
plemental material). The majority of index cases (21 of 30; 70%)
showed recessive inheritance, including four cases of compound
heterozygote inheritance, thereby dramatically increasing the
number of pathological recessive hyperekplexia alleles in the lit-
erature. Consistent with previous studies, all nonsense and dele-
tion/frameshift mutations were associated with recessive cases of
hyperekplexia, whereas missense mutations transmit in either a
dominant or recessive manner depending on their relative posi-
tion in the GlyR 1 subunit or coinheritance in compound het-
erozygotes (supplemental Fig. S1D, available at www.jneurosci.
org as supplemental material). Interestingly, recessive mutations
were scattered throughout the 1 GlyR subunit, whereas domi-
nant mutations were specifically clustered in and around the
pore-lining M2 domain (supplemental Fig. S1B,C, available at
www.jneurosci.org as supplemental material).
Electrophysiological analysis of GlyR 1 subunit mutants
To determine the functional effects of GLRA1mutations, WT or
mutant human 1 subunits were transiently expressed in
HEK293 cells either as homomeric1 or heteromeric1GlyRs.
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Recessive variants
Most recessive mutations (R65W, R252C, G254D) failed to gen-
erate currents either as homomeric or heteromeric GlyRs on ap-
plication of 30mM glycine (Fig. 1A, Table 2). One novel recessive
mutation, D165G, induced detectable, but significantly reduced,
maximum currents compared with WT, regardless of whether it
was expressed as a homomer or heteromer. Notably, the glycine
sensitivity of this mutant was markedly decreased (Fig. 1B; sup-
plemental Fig. S2, available at www.jneurosci.org as supplemen-
tal material). The mutation R392H, identified as a homozygous
recessive mutation in this study, was previously identified as
being part of a compound heterozygote (R252H and R392H)
(Vergouwe et al., 1999). Consistent with previous findings, ex-
pression of homomeric R392H mutant in HEK293 cells did not
induce detectable currents (n 	 20 for whole-cell patching
clamp; n
 2000 cells for automated screening). However, coex-
pression with GlyR  produced small but detectable currents
(Imax	 3023 925 pA; n	 6) (Fig. 1A) that exhibited a signif-
icant increase in glycine EC50.
Dominant variants
Two novel dominant mutations, Y128C and T265I, showed dra-
matically reduced Imax values compared with WT heteromers
(Fig. 1A, Table 2).When expressed as 1T265I homomers, 30mM
glycine consistently generated currents with magnitudes1% of
WT current levels (Imax	 165.44 36.6 pA; n	 11; p 0.0001
vsWT). In contrast, when 30mM glycine was applied to untrans-
fected cells, no significant deviation in baseline current was ever
observed (n
 20 gigasealed cells). The nH value for 1
T265I was
significantly reduced, suggesting a disruption in gating efficacy
(Colquhoun, 1998). However, when 1T265I was coexpressed
with the  subunit, the heteromeric glycine-mediated current
was easily detectable and a 20-fold increase in Imax was observed,
although it remained significantly less than values observed in
WT heteromers (Fig. 1A). In both homomeric and heteromeric
configurations, T265I exhibited a signifi-
cantly increased glycine EC50 (Fig. 1C, Ta-
ble 2). Last, the recurrent mutation
G342S, identified in two dominant index
cases in this study and in previous studies
(Rees et al., 2001), induced Imax currents
and a glycine EC50 value comparable with
that of WT GlyRs.
Compound heterozygosity
Hemizygous missense mutations, R65L,
E103K, and S231N, coinherited with large
deletions or nonsense mutations (in cases
7, 10, and 18, Table 1; supplemental Fig.
S1D, available at www.jneurosci.org as
supplemental material) were also ana-
lyzed. R65L, coinherited with Exon4-7,
generated no current when expressed in
HEK293 cells (Fig. 1A). This was predict-
able, since the positively charged R65 res-
idue is an important glycine binding
determinant (Grudzinska et al., 2005). By
contrast,mutations E103K and S231Nbe-
haved differently from conventional re-
cessive missense mutants despite being
coinherited with frameshift (L184fs21X)
and nonsense (S296X) mutations, respec-
tively (supplemental Fig. S1D, available at
www.jneurosci.org as supplemental ma-
terial). This should mean that 1E103K and 1S231N are the only
functional copies of GlyR subunits in vivo. Surprisingly, both
S231N and E103K, either as homomeric 1 or heteromeric 1
GlyRs, generated fully functional channels with Imax currents
compatible withWTGlyRs at 30mM glycine (Fig. 1A). However,
the EC50 for glycine was significantly increased in 1
E103K and
1S231N GlyRs relative to WT 1 controls (Fig. 1D, Table 2;
supplemental Fig. S2, available at www.jneurosci.org as supple-
mental material). Unsurprisingly, both S296X and L184fs21X
mutants failed to generate functional channels as either ho-
momers or heteromers.
GlyR1 T265 is a novel determinant of PTX sensitivity
PTX, a botanical alkaloid, potently inhibits homomeric 1-3
GlyRs, whereas the corresponding heteromeric  GlyRs are in-
sensitive (Hawthorne et al., 2006). ForWT and all other 1 GlyR
mutants investigated in this study, PTX (100M) strongly inhib-
ited currents in cells expressing homomeric 1 GlyRs, but not
heteromeric 1 GlyRs. One exception to this was the hetero-
meric 1T265I GlyR mutant, which displayed an anomalously
high PTX sensitivity (Fig. 2A). Individual PTX dose–responses in
the 1T265I GlyR were fitted with an averaged half-maximal
inhibitory concentration (IC50) of 12.7  0.82 M and an nH of
1.126 0.103 (Fig. 2A). This IC50 is significantly lower than the
corresponding values of the heteromeric 1  GlyR, which have
previously been determined at 219  28 M (Hawthorne et al.,
2006). Site-directed mutagenesis studies have demonstrated that
M2 structure is an important constraint for the antagonistic ac-
tivity of PTX as mutations to various GlyR 1 pore-lining resi-
dues, G254, T258, S267, R271, reduce the inhibitory potency of
PTX (Shan et al., 2001; Dibas et al., 2002). Structural analysis
predicted that T265 forms a part of pore-lining residues, along
withG254, T258, and S267, andplays an important role formain-
taining a minimum pore diameter by forming a hydrophobic
A
B C D
Figure 1. Imax values at saturating glycine responses and dose–response characteristics of glycine-induced currents. A, Maxi-
mal GlyR currents were obtained from HEK293 cells expressing WT or mutant homomeric1 subunit GlyRs or heteromeric1
GlyRs at saturating glycine concentrations (up to 30 mM). HEK293 cells that did not generate any glycine-induced currents were
excluded from the analysis. *p 0.001 versusWT; †p 0.01 versus heteromer.B–D, The currents are shown as a percentage of
the maximal current for each cell. The solid-line dose–response curves represent GlyR1 homomers, whereas the dashed curves
represent GlyR1 heteromers. Error bars indicate SEM.
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bond with Q266 in adjacent M2 domain (Miyazawa et al., 2003).
T265 in the M2 domain represents a novel determinant of PTX
sensitivity.
GlyR1 Y128C causes spontaneously open channels
The novel variant Y128C is the second dominant hyperekplexia
mutation found in the LBD (supplemental Fig. S1C, available at
www.jneurosci.org as supplemental material). The only previ-
ously reported LBD dominant mutation, R218Q, decreases both
total and cell surface expression levels (Miraglia Del Giudice et
al., 2003). By contrast, the Y128C mutant formed spontaneously
opening channels when expressed as either homomeric 1Y128C
or heteromeric 1Y128CGlyRs (Fig. 2B). Application of 100M
PTX, but not 10 M strychnine, significantly reduced inward
currents (472 71 pA; n	 25) in the absence of glycine, suggest-
ing the closure of spontaneously open channels (Fig. 2C). Fur-
thermore, the slope conductance between80 and80 mV for
Y128C in the absence of glycine was significantly higher com-
pared with WT (Y128C, 2.95 0.48 nS, n	 7; WT, 0.55 0.09
nS, n 	 6; p  0.001) (Fig. 2D). Application of PTX (100 M)
reduced the leak conductance of Y128C by 35%, whereas resting
conductances for WT were not affected by PTX. As expected
from the smaller glycine current produced by Y128C compared
with WT (Fig. 1A), application of 1 mM glycine resulted in
smaller slope conductance in Y128C than in WT. Since this is a
dominant mutation, we sought to investigate how leak magni-
tude changed when 1Y128C coexpressed with WT subunits.
Thus, 1Y128C was mixed with different ratios of WT 1 and
coexpressed with the I-sensitive YFPI152L. Using an automated
live-cell imaging system, the glycine dose–response characteris-
tics were determined by quantifying the fluorescence change after
the application of increasing concentrations of glycine (0.001–10
mM). After the application of a saturating glycine concentration
(1 mM), 
90% of fluorescent cells transfected with 1 and
YFPI152L displayed fluorescence quench, indicating
90% of co-
transfection efficiency of 1 and YFPI152L. The EC50 of WT 1
Table 2. Functional analysis of novel hyperekplexia mutations
1
Homomeric1 Heteromeric1
Functional effectsGlycine EC50 (mM) nH Glycine EC50 (mM) nH
AD WT 20.74 7.27 (6) 1.86 0.3 23.24 7.59 (6) 1.17 0.31
Y128C — — — — Tonic opening of channel
T265I 302.37 97.38* (3) 0.84 0.15 774.83 219.53* (6) 1.01 0.1 Shift of EC50
G342S 62.26 6.0 (6) 2.40 0.18 84.07 11.69 (11) 1.8 0.24 Rare SNP
Recessive R65W — — — — Trafficking
D165G 145.33 23.20 ‡ (6) 1.49 0.14 212.88 56.83 † (4) 1.66 0.4 Trafficking
R252C — — — — Trafficking
G254D — — — — Trafficking
R392H — — 164.79 35.73 † (6) 2.07 0.21 Trafficking
Compound R65L# — — — — No current
Exons 4-7 ND
Compound E103K 540.7 148.3* (8) 1.05 0.13 757.52 147.72* (6) 1.11 0.05 Shift of EC50
L184fs21X — — — — Trafficking
Compound S231N 262.15 31.89 † (5) 1.32 0.16 383.81 132.57 † (5) 1.75 0.39 Shift of EC50
S296X — — — — Trafficking
*,†,‡Statistically different fromWT GlyR1/GlyR1 (*p 0.001, †p 0.01, ‡p 0.05).
A B
D
C E
Figure 2. Novel effects of dominant mutations identified in this study. A, The GlyR 1 T265I mutation converted PTX-insensitive heteromeric 1 T265I GlyRs to PTX-sensitive receptors. Top,
Examples of PTX current inhibition produced by 1 T265I GlyRs when an increasing concentration of PTX was applied in the presence of an EC50 concentration of glycine. Bottom, Inhibitory
dose–response curve. Parameters of best fit are given in the text. B–E,1Y128C GlyRs generated tonic currents when expressed in HEK293 cells as either homomeric or heteromeric GlyRs. B, Examples of
glycine-induced currents producedby1 Y128C. C, A representative trace of a decrease in inward current induced by PTX (100M) in the absence of glycine. ForWT, no detectable currentwas induced
byPTXor in theabsenceof agonist.D, Current–voltage relationshipofWT/Y128C receptors. I–V curvesweremeasuredbywhole-cell patch-clamp recordings (1) in theabsenceof agonist/antagonist
(control), (2) in the presence of 100M PTX, and (3) in the presence of 1mM glycine.1 Y128C shows unusually large resting conductances in the absence of glycine (control). *p 0.001 versusWT.
E, Glycine responses of 2000 cells transfected with1 Y128C cDNA, or with combinations of1 Y128C cDNA with1WT in different ratios (Y128C:WT, 1:1, 2:1, or 4:1).
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GlyRs was similar to that produced by patch clamp (19.3  3.4
M for YFP imaging, n
 2000; 20.7 7.3 M for electrophysi-
ology, n	 6). Cells transfected with Y128C (n
 2000) displayed
a maximum fluorescent change in the absence of glycine (Fig.
2E). Cells transfected with an equal amount of Y128C and WT
generated dose–response curves similar to that of cells expressing
Y128C, confirming the dominant effect of Y128C on GlyR
function.
Defective subcellular localization is the major mechanism
associated with recessiveGLRA1mutations
For eachmutant, the number of cells expressing functional GlyRs
was determined using a live-cell imaging system in which
HEK293 cells were cotransfected with mutant or WT GlyR 1
plus YFP. Screening of
1500 cells transfectedwith each different
GlyR mutants demonstrated that recessive mutations display no
change in florescence intensity indicating significant reduction in
the number of functional channels, further supporting the ab-
sence of glycine-mediated currents in cells expressing these mu-
tants (Fig. 3A). Dominant mutations Y128C and T265I and
hemizygous missense mutations E103K and S231N displayed an
expression level comparable with that of WT GlyRs. To investi-
gate the effects of coexpression of compound heterozygote
mutations, we screened 
2000 HEK cells cotransfected with
compound mutations (S296X plus S231R/E103K plus L184fs21X).
Both S296X and L184fs21X mutants show loss of function; how-
ever, they did not demonstrate any dominant-negative effects on
the expression of S231R or E103K, respectively (Fig. 3A). Previ-
ously, S296X was reported to exert dominant-negative effects on
the WT GlyR 1 subunit by reducing Cl current density from
170 pA/pF (WT) to 100 pA/pF (S296X plus WT) (Bellini et
al., 2007). However, when HEK293 cells were transfected with
S296X andWTGlyR1 in theYFP automated system (n
 2000),
no significant change in EC50 or maximum current was observed
compared with WT alone.
Biotinylation labeling assays
Hyperekplexia mutants with low-level expression of functional
GlyRs were further investigated for the surface expression. Bioti-
nylation of cell surface proteins revealed that the reduction in the
number of functional channels observed in recessive mutants is
attributable to the decreased cell surface expression ofGlyRs (Fig.
3B,C). Although the whole-cell expression of recessive mutants
was comparable with that ofWTGlyR 1, cell surface expression
levels were significantly decreased. These data provide additional
support for a previous study on the mechanisms of recessive
mutations (Villmann et al., 2009). As expected, mutants T265I
and R392H displayed robust cell surface expression. The hemi-
zygous mutation, R65L, identified in a compound heterozygous
case (Table 1, case 7), generated no current but had similar levels
of surface protein expression compared with WT. By contrast,
the recessive mutation R65W showed a significant reduction in
the level of surface protein expression but a similar level of whole-
cell expression. The possible explanation for this residue-specific
cell surface difference is described below in the molecular mod-
eling section. For the dominant T265I mutation, there was no
alteration in the cell surface expression indicating that the de-
creased level of T265I GlyRs is attributable to nonfunctional
surface-targeted channels rather than a reduction in surface
expression.
Molecular modeling provides converging evidence with
functional assays
Structural modeling findings for GlyR 1 mutants are summa-
rized in supplemental Table S1 (available at www.jneurosci.org as
supplemental material) and Figure 4A. Several mutations are
predicted to result in the marked rearrangement of TM regions,
including Y128C and T265I, which both produce low currents
(Fig. 4B). Conversely, E103K and S231N mutants are predicted
to result in onlyminor rearrangements of TM regions, consistent
with these mutants showing robust glycine-gated currents (sup-
plemental Fig. S3A, available at www.jneurosci.org as supple-
mental material). Relaxation of the -strand structure in the
vicinity of the glycine binding site was predicted for E103K,
S231N, T265I, and R392H, and this could explain the observed
increases in EC50 in our functional assays. By contrast, the R65W,
R252C, andG254Dmutants displayed extension of either theM2
orM3 helix into the LBD interface, possibly explaining their lack
of cell membrane expression. The main predicted differences be-
tween R65L and R65W models can be observed in the -strand
structure of the extracellular domain, which is enhanced in
R65W compared with R65L and WT (supplemental Fig. S3B,
available at www.jneurosci.org as supplemental material). Com-
parisons of the models of heteropentameric GlyRs 1 and GlyR
1Y128C (Fig. 4C) revealed that Y128C is predicted to disrupt
the packing of the 1 subunit M2 andM3 helices and, as a result,
†
A B C
Figure3. Expression level ofmutant GlyRs.A, TheWThumanGlyR1 subunit or hyperekplexiamutantswere expressed inHEK293 cells, either as homomeric or heteromeric GlyRs, togetherwith
YFP. Thenumber of cells expressing functionalmutant channelswas quantified (and comparedwith that of theWT subunit) using a YFP-based screening assay. Fluorescent cells that showed
20%
of fluorescent change (quench) after the application of a saturating concentration of glycinewere considered to be expressing functional GlyRs. *R65L is coinheritedwithExon4-7 in case 7 (Table
1).B, Biotinylation assay showed that recessivemutantswere expressed in similar levels ofwhole-cell protein expression (total) but reduced cell surface protein expression (surface) comparedwith
WT receptors. C, Surface expression of the GlyR1mutants was quantified using ImageJ software and expressed as a percentage of WT GlyR1. †p 0.0001. Fifty micrograms of protein lysates
were loaded in the each lane. Error bars indicate SEM.
Chung et al. •Mechanisms of Hyperekplexia Mutations J. Neurosci., July 14, 2010 • 30(28):9612–9620 • 9617
cause disorder of pore architecture.
Y128C produced a marked rearrange-
ment of the M2 helix, resulting in a gen-
eral slackening of the pore and loss of
intimate contact between the key pore-
lining residues, R252, G254, and T265
(Fig. 4D). Thus, it appears that the intro-
duction of a short -helix in the LBD
(supplemental Fig. S3C, available at www.
jneurosci.org as supplementalmaterial) at
residues 142–145 by the Y128C mutation
disrupts 1 subunit interactions. This
region is predicted to operate in conjunc-
tion with residues 183–185, on the other
side of the 1 subunit at the interface be-
tween the LBD and TM domains, in coor-
dination of  subunit packing.
Discussion
This study represents by far the largest
multicenter screening program in hy-
perekplexia to date with concomitant
functional characterization of GLRA1
mutations in hyperekplexia. Our direct
sequencing screening programof 88 index
cases, collected over 15 years, has identi-
fied 19 GLRA1mutations within 30 index
cases, of which 21 cases were inherited in
recessive or compound heterozygote
modes (Table 1). This study increases the
compendium of hyperekplexia associated
GLRA1 mutations by 42% and effectively
doubles the number of gene-positive in-
dex cases known in the literature. Consis-
tent with previous studies, all nonsense
and intragenic deletion mutations were
associated with recessive cases of hyperek-
plexia, confirming that haploinsufficiency
is not a feature of this disorder. Hyperek-
plexia has traditionally been considered to
be a dominant disorder (Harvey et al.,
2008) mostly driven by the identification
of multiply affected dominant families
with a linked bias of M2 mutations and
the relative high frequency of R271Q/L al-
leles in Caucasians. However, several re-
cent studies have provided increasing
evidence for the contribution of recessive alleles, led by the high
frequency of Exon 1-7 as a founder effect in the Turkish and
Kurdish populations (Gilbert et al., 2004; Becker et al., 2006;
Sire´n et al., 2006). This latest study confirms that, on an index
case population basis, the recessive inheritance of
hyperekplexia is more common than dominant, although they
are closely matched in their relative contribution. Combined
with the data from the second major gene mutated in hyperek-
plexia, the glycine transporter 2 gene, SLC6A5 (Rees et al., 2006),
in which compound heterozygosity and homozygous mutant al-
leles predominate, then the balance moves toward hyperekplexia
being a predominantly recessive disorder.
As revealed by previous studies (Harvey et al., 2008), the clinical
phenotypes of patients with recessive mutations were not as se-
vere as the phenotype of hyperekplexia in animal models, in
which recessive mutations are associated with more severe out-
comes leading to premature death (Buckwalter et al., 1994), in-
dicating the likely existence of compensatory mechanisms in
humans. Patients with recessive or null mutations in GLRA1,
however, were associated with a spectrum of developmental dis-
orders from motor delay to learning difficulties and challenging
behavior (supplemental Table S2, available at www.jneurosci.org
as supplemental material). Parents who were heterozygous carri-
ers of the recessive/compound mutations did not present with
clinical symptoms reminiscent of hyperekplexia. However, dom-
inant mutations in index cases were associated with one affected
parent within the nuclear family structure. In addition to novel
insights of the molecular genetics of hyperekplexia, we have used
high-throughput functional assays to reveal new pathogenic
mechanisms associated with GLRA1 mutations. Of 12 novel
GLRA1 mutations identified, all were submitted to functional
analysis with the exception of the homozygous stop codon alleles
Figure 4. Structural modeling of GlyR 1 mutants. A, GLRA1 mutations are shown on GlyR 1 subunit model. B, Structural
modeling of GlyR 1, showing wild-type structure, introduction of short -helical structure in extracellular domain of Y128C
mutant (indicated by thick arrow) associated with tonic opening, marked rearrangement of transmembrane regions in T265I
mutant associated with low current; and relaxation of structure in the vicinity of the glycine binding site (regular long arrow),
concomitant with observed increases in EC50. C, Pentameric form (2, 3) of1 WT and Y128C mutant, side view, extracellular
end at the top, showing1 subunits in pink (WT) or green (Y128Cmutant), subunits in blue, Y128 in brown, C128 inmagenta,
sections 142–145 and 183–185 in red ( conformation) and yellow ( conformation) as appropriate. R252 (where visible) at the
cytoplasmic end, colored by element (blue), G254 (cytoplasmic end) in orange, and T265 (mid-membrane) in purple. D, Pentam-
eric form, view from extracellular end, showing considerable disruption of subunit packing in the1 Y128C polypeptide, resulting
in slackening around the ion pore and loss of intimate WT arrangement of key pore-lining residues G254 (orange), T265 (by
element, red), and R252 (by element, blue).
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(Y197X and Y202X) and large deletions (e.g., Exon 4-7) in
which the outcomes are unambiguous. This evidence-based ap-
proach is essential for establishing the pathophysiological princi-
ples underlying the abnormal startle response.
Our data essentially confirm the existence of three basic GlyR
channelopathy mechanisms. (1) Cell surface expressed receptors
that do not function correctly because of dominant mutations
that compromise glycine ligand binding, alter apparent agonist
sensitivity or cause chloride conductance defects; (2) recessive
trafficking mutants in which pentameric assembly or transition
through the transcription/translation processes conspire to cause
a deficiency of cell surface targeting or insertion of GlyRs; (3)
recessive null genotypes in which the creation of functional 1
pentamers is precluded, leading to a deficit in glycinergic neuro-
transmission in which compensatory mechanisms prevent a le-
thal clinical outcome. In addition, we have also determined that
T265 in the M2 domain is an important determinant of the PTX
activity, and that different substitutions at one position in GlyR
1 (R65L, R65W) result in quite different outcomes in functional
analysis and molecular modeling. The only exception to the
pathogenic trends was missense substitution G342S in which
no indication of functional deficits was found, suggesting that
this variation could simply be a rare SNP. Alternatively, given
the location of this residue in the M3–M4 domain, perhaps
G342S disrupts an as-yet-uncharacterized GlyR–accessory
protein interaction.
Our study has also identified a new pathogenic mechanism in
hyperekplexia: spontaneously opening GlyRs. A single dominant
missensemutation, Y128C, in the GlyR1 subunit LBD, resulted
in tonic channel opening in the absence of agonist. Spontaneous
channel activity has been recognized as a pathogenic mechanism
in other episodic disorders including congenital muscle disease,
cardiac arrhythmias, and hypokalemic periodic paralysis
(Paavola et al., 2007; Sokolov et al., 2007; Treves et al., 2008).
Previous GlyR 1 site-directed mutagenesis studies have also
identified three residues causing spontaneously opening: D97R
and F99A in the LBD and A288W in M3 (Mihic et al., 1997;
Beckstead et al., 2002; Miller et al., 2008). Indeed, our structural
modeling indicates that Y128 is located in close proximity to D97
and F99. Y128C, F99A, and D97R are all predicted to induce the
same short -helix in the LBD directly overlying the TM regions
suggesting a common mechanism of tonic channel opening. By
contrast, A288W, which is located near the M3 extracellular
boundary, appears to achieve tonic opening by an alternative
mechanism. The large tryptophan residue projects outward from
M3 and probably interferes with subunit packing. Although the
precise mechanisms underlying the spontaneous channel activa-
tion are unclear at present, a recent study revealed that agonist
binding to GlyR 1 initiates rearrangements of the LBD inner
-sheet to trigger additional movements for removing channel
gating (Pless and Lynch, 2009). Since Y128 lies in loop E in the
inner -sheet, the tyrosine-to-cysteine substitution at residue
128 is expected to interrupt the -sheet structure, thereby favor-
ing the open conformation. How does spontaneous GlyR activity
produce hyperekplexia? It might be expected that overactive
GlyRs would chronically inhibit postsynaptic motor neurons.
However, this would lead to a long-term dampening of motor
neuron activity, which is not observed in hyperekplexia patients.
Given that the carrier of Y128C has classical hyperekplexia symp-
toms, it is more likely that compensatory mechanisms restore
normal ionic gradients and neuronal excitability and that the hy-
perekplexia phenotype is attributable to a reduced magnitude of
glycine-activated inhibitory currents throughY128CmutantGlyRs.
This study has revealed novel and recurrent mutations com-
bining this with high-throughput functional analysis to confirm
pathophysiological and clinical conclusions. For GLRA1 gene-
negative patients, additional analysis awaits for SLC6A5, GLRB,
GPHN, and other loci that have previously underlined the genetic
heterogeneity and systems biology approach in hyperekplexia
(Harvey et al., 2008). As molecular genetics enters the next tech-
nical revolution to third-generation sequencing and array-based
analysis, it must not be forgotten that careful functional charac-
terization of genotypes must accompany the sequencing data if
the correct in vivo mechanisms are to be identified in hyperek-
plexia and other neurological disorders. Our functional analysis
of the novel mutations revealed new mechanisms of action in-
cluding the first description of GlyR tonic opening (Y128C), an
important determinant of PTX binding (T265I), and the first
mutations in the glycine binding site (R65) revealing sub-
stitution-specific effects on cell surface trafficking. Several lines of
convergent evidence, including biophysical characterization, cell
surface expression, andmolecular modeling, all provide a patho-
physiological basis for the dysfunction of an evolutionarily con-
served, ancient startle response.
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